Atorvastatin lowers ⁶⁸Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes.

ABSTRACT:

Aims/hypothesis

Inflammation is a core component of residual cardiovascular risk in type 2 diabetes. With new anti-inflammatory therapeutics entering the field, accurate markers to evaluate their effectiveness in reducing cardiovascular disease are paramount. Gallium-68-labelled DOTATATE (⁶⁸Ga-DOTATATE) has recently been proposed as a more specific marker of arterial wall inflammation than ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG). This study set out to investigate whether ⁶⁸Ga-DOTATATE uptake is amenable to therapeutic intervention in individuals with type 2 diabetes.

Methods

Individuals aged >50 years with type 2 diabetes underwent ⁶⁸Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) at baseline and after 3

SUBMITTER: Oostveen RF 

PROVIDER: S-EPMC10542709 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature